NeuroPace Reports Record Q2 Revenue

NeuroPace (NASDAQ:NPCE) reported second quarter 2025 earnings on August 12, 2025, delivering record revenue of $23.5 million, up 22% year-over-year, with gross margin of 77.1% and an increased full-year revenue outlook of $94 million to $98 million. Major strategic highlights include strong core RNS system sales, positive progress in the NAUTILIST trial for generalized epilepsy, and successful debt refinancing supporting financial flexibility. The following insights detail drivers of sustainable growth, expansion initiatives, and implications for long-term investors.Revenue increased by $4.2 million year-over-year, propelled by rising implant volumes and expanded prescriber engagement, while Dixie Medical product sales are being phased out. Gross margin rose to 77.1% from 73.4% year-over-year, and RNS system gross margin exceeded 80%, reflecting improved manufacturing efficiency and favorable product mix.The significant gross margin improvement, coupled with operating expense growth held below revenue growth (13% YoY vs. 22% YoY, respectively, both excluding nonrecurring items), enhances underlying operating leverage.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool